Nanjing Leads Biolabs Co., Ltd. (9887.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$37.28 (+6.64%) as of
Key statistics
- Market cap
- 7.27B
- Forward P/E
- -24.17
- EPS (TTM)
- -1.630
- Dividend yield
- 0.00%
- 52-week range
- 34.600 – 97.500
- Revenue (TTM)
- 213.22M
- Profit margin
- -125.20%
- Analyst target
- HK$106.13
- Volume
- 2.26M
About Nanjing Leads Biolabs Co., Ltd.
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company was founded in 2012 and is headquartered in Nanjing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nanjing, China
- Employees
- 259
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.